Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells
Xi Chen,Jianjun Chang,Qiudong Deng,Jie Xu,Thi A. Nguyen,Lauren H. Martens,Basar Cenik,Georgia Taylor,Kathryn F. Hudson,Jaegwon Chung,Kimberley Yu,Phillip Yu,Joachim Herz,Robert V. Farese,Thomas Kukar,Malu G. Tansey
DOI: https://doi.org/10.1523/jneurosci.5336-12.2013
2013-01-01
Journal of Neuroscience
Abstract:Progranulin (PGRN) is a secreted glycoprotein expressed in neurons and glia that is implicated in neuronal survival on the basis that mutations in theGRNgene causing haploinsufficiency result in a familial form of frontotemporal dementia (FTD). Recently, a direct interaction between PGRN and tumor necrosis factor receptors (TNFR I/II) was reported and proposed to be a mechanism by which PGRN exerts anti-inflammatory activity, raising the possibility that aberrant PGRN–TNFR interactions underlie the molecular basis for neuroinflammation in frontotemporal lobar degeneration pathogenesis. Here, we report that we find no evidence for a direct physical or functional interaction between PGRN and TNFRs. Using coimmunoprecipitation and surface plasmon resonance (SPR) we replicated the interaction between PGRN and sortilin and that between TNF and TNFRI/II, but not the interaction between PGRN and TNFRs. Recombinant PGRN or transfection of a cDNA encoding PGRN did not antagonize TNF-dependent NFκB, Akt, and Erk1/2 pathway activation; inflammatory gene expression; or secretion of inflammatory factors in BV2 microglia and bone marrow-derived macrophages (BMDMs). Moreover, PGRN did not antagonize TNF-induced cytotoxicity on dopaminergic neuroblastoma cells. Last, co-addition or pre-incubation with various N- or C-terminal-tagged recombinant PGRNs did not alter lipopolysaccharide-induced inflammatory gene expression or cytokine secretion in any cell type examined, including BMDMs fromGrn+/− orGrn−/− mice. Therefore, the neuroinflammatory phenotype associated with PGRN deficiency in the CNS is not a direct consequence of the loss of TNF antagonism by PGRN, but may be a secondary response by glia to disrupted interactions between PGRN and Sortilin and/or other binding partners yet to be identified.